Posted by Michael Wonder on 11 Jun 2020
Tafamidis for treating transthyretin amyloid cardiomyopathy
11 June 2020 - The Department of Health and Social Care has asked the NICE to produce guidance on using tafamidis in the NHS in England.
Tafamidis is not recommended, within its marketing authorisation, for treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in adults.
Inconsistent results on how effective tafamidis is for different types and stages of ATTR-CM mean that the evidence is uncertain.
